How a Biologics CDMO Adds Value to mAbs Development & Manufacturing Programs

Date Published: Jun 16, 2023

Last Modified: Oct 20, 2023

Author: Abby Sorensen,
Marketing Manager,
Scorpius BioManufacturing

A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle

The growing number of monoclonal antibodies (mAbs), and the maturation of their process development and manufacturing, have led to contract development and manufacturing organizations (CDMOs) playing an increasingly important role in expediting these programs’ path to commercialization. This infographic explores how an experienced biologics CDMO adds value throughout a mAb’s lifecycle.




About the Author: Abby Sorensen joined Scorpius BioManufacturing in February 2023 after spending almost nine years in biopharma media with Life Science Connect. Her experience includes business development, content creation and strategy, trade show planning and execution, and project management. She has consulted on biopharma marketing strategies for clients ranging from Fortune 500 companies to startups. Abby graduated valedictorian from Allegheny College in Meadville, Pennsylvania with a BA in Women’s Studies.